Evidence map›Paper›PMID 31648945›Full record

ReviewAdvances in biological regulation2020

Structural analyses of inositol phosphate second messengers bound to signaling effector proteins.

Raymond D Blind

Open access · greenAbstract readReview
In one paragraph

Review in Advances in biological regulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. The importance of IP6 for ADAR RNA-editing enzymes and antiviral defense.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Multiple inositol phosphate species enhance stability of active mTOR.bioRxiv : the preprint server for biology · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Stable Isotopomers ofACS central science · 2022
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Inositol phosphate kinases in the eukaryote landscape.Advances in biological regulation · 2021
    Article
  18. Article
  19. Signalling Properties of Inositol Polyphosphates.Molecules (Basel, Switzerland) · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Raymond D BlindDepartment of Medicine, Division of Diabetes, Endocrinology and Metabolism, Vanderbilt University Medical Center, USA; Department of Biochemistry, Vanderbilt University School of Medicine, USA; Department of Pharmacology, Vanderbilt University School of Medicine, USA. Electronic address: ray.blind@vanderbilt.edu.
Vanderbilt University Medical Center · US

Funding

Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI John Michael Stafford · 2012 to 2026
$29.3M
TRANSGENIC MOUSE/ ES CELL SHARES RESOURCESP60DK020593 · NIDDK · VANDERBILT UNIVERSITY · PI ELASY, TOM A · 1986 to 2011
$28.1M
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
TRAINING IN PHARMACOLOGICAL SCIENCEST32GM007628 · NIGMS · VANDERBILT UNIVERSITY · PI BARNETT, JOEY VICTOR, KAVALALI, EGE T · 1985 to 2022
$11.2M
IPMK function in chromatinR01GM132592 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLIND, RAYMOND DANIEL · 2020 to 2023
$1.5M
Cancer cell signaling through lipids complexed to proteinsK01CA172957 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLIND, RAYMOND DANIEL · 2012 to 2015
$449k
A new kinase inhibitor for glioblastomaR21CA243036 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BLIND, RAYMOND DANIEL · 2019 to 2020
$407k
NCI NIH HHS K01 CA172957NCI NIH HHS R21 CA243036NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK063720NIDDK NIH HHS P60 DK020593NIGMS NIH HHS R01 GM132592NIGMS NIH HHS T32 GM007628
6 · The paper itself

Abstract

The higher-order inositol phosphate second messengers inositol tetrakisphosphate (IP4), inositol pentakisphosphate (IP5) and inositol hexakisphosphate (IP6) are important signaling molecules that regulate DNA-damage repair, cohesin dynamics, RNA-editing, retroviral assembly, nuclear transport, phosphorylation, acetylation, crotonylation, and ubiquitination. This functional diversity has made understanding how inositol polyphosphates regulate cellular processes challenging to dissect. However, some inositol phosphates have been unexpectedly found in X-ray crystal structures, occasionally revealing structural and mechanistic details of effector protein regulation before functional consequences have been described. This review highlights a sampling of crystal structures describing the interaction between inositol phosphates and protein effectors. This list includes the RNA editing enzyme "adenosine deaminase that acts on RNA 2" (ADAR2), the Pds5B regulator of cohesin dynamics, the class 1 histone deacetylases (HDACs) HDAC1 and HDAC3, and the PH domain of Bruton's tyrosine kinase (Btk). One of the most important enzymes responsible for higher-order inositol phosphate synthesis is inositol polyphosphate multikinase (IPMK), which plays dual roles in both inositol and phosphoinositide signaling. Structures of phosphoinositide lipid binding proteins have also revealed new aspects of protein effector regulation, as mediated by the nuclear receptors Steroidogenic Factor-1 (SF-1, NR5A2) and Liver Receptor Homolog-1 (LRH-1, NR5A2). Together, these studies underscore the structural diversity in binding interactions between effector proteins and inositol phosphate small signaling molecules, and further support that detailed structural studies can lead to new biological discovery.

Indexed as

Second Messenger SystemsAdenosine DeaminaseAgammaglobulinaemia Tyrosine KinaseCrystallography, X-RayDNA-Binding ProteinsHistone Deacetylase 1Histone Deacetylase 3Histone DeacetylasesHumansInositol PhosphatesReceptors, Cytoplasmic and NuclearRNA-Binding ProteinsTranscription FactorsADARB1 protein, humanAdenosine DeaminaseAgammaglobulinaemia Tyrosine KinaseBTK protein, humanDNA-Binding ProteinsHDAC1 protein, humanHistone Deacetylase 1Histone Deacetylase 3Histone DeacetylasesInositol PhosphatesNR5A2 protein, humanPDS5B protein, humanReceptors, Cytoplasmic and NuclearRNA-Binding ProteinsTranscription FactorsADAR2BtkHDAC1HDAC2HDAC3Higher-order inositol phosphatesInositol-binding proteinsInositol polyphosphate multikinase IPMKInositol regulated transcriptionIP4IP5IP6IP6 regulated gene expressionNR5A1 nuclear receptorPds5b

Identifiers

PMID31648945
PMCPMC7056587
OpenAlexW2980302040

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.